Form 4: Axogen Director Exercises Options, Sells Shares

Axogen Director Joseph A. Tyndall exercised stock options and subsequently sold the acquired common stock for a significant gain.

Summary

• Joseph A. Tyndall, a Director of Axogen, Inc. (AXGN), reported transactions on December 9, 2025, involving the exercise of stock options and the sale of common stock.
• Tyndall acquired 14,248 shares of common stock by exercising employee stock options at an exercise price of $7.04 per share.
• He also acquired 10,860 shares of common stock by exercising stock options at an exercise price of $10.95 per share.
• Immediately following the option exercises, Tyndall sold all 14,248 shares at a weighted average price of $30.977 per share.
• He also sold all 10,860 shares acquired from the second option exercise at the same weighted average price of $30.977 per share.
• The sales were executed in multiple transactions with prices ranging from $30.485 to $31.305 per share.
• The 14,248 non-qualified stock options were part of the 2024 annual equity grant for his service as a Director and vested on June 6, 2025.
• The 10,860 stock options were granted upon joining the Board and vested in three equal annual installments, with the first vesting on December 13, 2023.

Sentiment

Score: 7

Explanation: The filing reflects a director monetizing vested stock options, indicating personal financial planning rather than a direct statement on company performance. The significant profit realized is positive for the individual, and the transaction itself is a neutral event for the company's operational outlook.

Positives

• The Director realized a significant gross profit of approximately $340,965.86 from the sale of 14,248 shares (acquired at $7.04, sold at $30.977).
• An additional gross profit of approximately $217,416.42 was realized from the sale of 10,860 shares (acquired at $10.95, sold at $30.977).
• The total gross profit from these transactions amounted to approximately $558,382.28, indicating a successful monetization of vested equity compensation.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view this as a routine monetization of compensation by a director, which is generally a neutral event. It does not inherently signal a change in the company's fundamental performance or strategic direction.

Key Dates

Recommendation

The filing details a routine insider transaction where a director exercised vested stock options and sold the acquired shares. This is typically a personal financial decision and does not inherently signal a change in the company's fundamental outlook or performance. Therefore, a 'hold' recommendation is appropriate based solely on this Form 4, awaiting further company-specific or market-wide information.

Keywords

Axogen, AXGN, Form 4, insider trading, stock options, director, share sale, beneficial ownership